Resultados: 14

    European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)

    The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic...

    Spinal metastases and metastatic spinal cord compression

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neu...

    Guía de práctica clínica para el tratamiento del cáncer de próstata metastásico hormonosensible: guía en versión extensa

    El cáncer de próstata metastásico se presenta en el 20% de pacientes al momento del diagnóstico de cáncer de próstata (1). Los sitios comunes de diseminación metastásica locorregional son los ganglios linfáticos (99%) y huesos como pelvis, cadera y esqueleto axial (84%); mientras que las localiz...

    Regorafenib for previously treated metastatic colorectal cancer

    Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults. Commercial arrangement There is a simple discount patient access scheme for regorafenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS or...

    Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma

    Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. Commercial arrangement There is a commercial arrangement for nivolumab. NHS organisations can get...

    Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. Commercial arrangement There is a managed access agreement, which includes a patient access scheme, for trastuzumab derux...

    Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

    Next Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults. Commercial arrangement There is a commercial access agreement for nivolumab...

    GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer

    World J Clin Oncol; 13 (4), 2022
    Non-small cell lung cancer (NSCLC) is a heterogeneous disease accounting for approximately 85% of all lung cancers. Only 17% of patients are diagnosed at an early stage. Treatment is multidisciplinary and radiotherapy plays a key role in all stages of the disease. More than 50% of patients with NSCLC are...

    Brain tumours (primary) and brain metastases in adults: Last updated 29 January 2021

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care. In January 2021, we...

    Problema de Salud AUGE N°83: Cáncer Renal en personas de 15 años y más

    La incidencia del carcinoma de células renales (CCR) ha aumentado en las últimas décadas, siendo a nivel mundial el sexto cáncer más frecuentemente diagnosticado en hombres y el décimo en mujeres (1). Sin embargo, la sobrevida ha mejorado en las últimas tres décadas. Esto se ha dado, en parte, po...